In addition to established targets for MM, such as CD38 and CS1, recent research has explored alternative strategies, including the potential repositioning of DOTA-TATE as both a diagnostic and therapeutic tool in MM [131]. This evidence concerns the gene CD38 and Miyoshi myopathy.